---
title: "MBDB - Complete Profile"
substance: "MBDB"
chemical_name: "N-Methyl-1,3-benzodioxolylbutanamine"
category: "Empathogen"
legal_status: "Unscheduled (most countries), Research Chemical"
description: "MDMA's gentler cousin - longer-lasting empathy with less stimulation and smoother comedown"
permalink: "/dyos-domain/substances/mbdb/"
---

<div class="substance-profile-header">
  <div class="container">
    <nav class="breadcrumb">
      <a href="/dyos-domain/">Dyo's Domain</a> 竊・<a href="/dyos-domain/empathogens/">Empathogens</a> 竊・<span>MBDB</span>
    </nav>
    
    <div class="substance-hero">
      <div class="substance-info">
        <h1>汳 MBDB</h1>
        <h2 class="chemical-name">N-Methyl-1,3-benzodioxolylbutanamine</h2>
          <!-- Add to Profile Button -->
        <button id="add-to-profile-btn" class="add-to-profile-btn not-in-profile" 
                data-substance="MBDB" 
                data-category="Empathogens" 
                data-chemical="N-Methyl-1,3-benzodioxolylbutanamine">
          + Add to My Profile
        </button>
        
        <div class="alternative-names">
          <h3>Alternative Names & Slang</h3>
          <div class="names-grid">
            <div class="name-category">
              <h4>Chemical Names</h4>
              <span>Methylbenzodioxolylbutanamine</span> 窶｢ <span>3,4-Methylenedioxybutanamine</span>
            </div>
            <div class="name-category">
              <h4>Research Designations</h4>
              <span>MBDB</span> 窶｢ <span>Eden</span> 窶｢ <span>Methyl-J</span>
            </div>
            <div class="name-category">
              <h4>Street Names</h4>
              <span>Gentle E</span> 窶｢ <span>Soft Roll</span> 窶｢ <span>Buddha</span>
            </div>
            <div class="name-category">
              <h4>PiHKAL Reference</h4>
              <span>Entry #109</span> 窶｢ <span>Shulgin's "Gentler MDMA"</span>
            </div>
          </div>
        </div>
        
        <div class="substance-meta-large">
          <span class="category empathogen">Empathogen</span>
          <span class="legal-status research-chemical">Research Chemical</span>
          <span class="duration long">6-8 hours</span>
        </div>
      </div>
      
      <div class="substance-visual">
        <div class="substance-image">
          <img src="{{ '/assets/substances/mbdb.jpg' | url }}" alt="MBDB white crystalline powder" class="substance-photo">
        </div>
        <div class="molecule-structure">
          <div class="structure-placeholder">
            <p>洫ｬ C竄≫ｂH竄≫ｇNO竄・/p>
            <p>MW: 207.27 g/mol</p>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>

<div class="container">
  
  <div class="profile-grid">
    
    <div class="profile-section identification">
      <h3>沐 Physical Identification</h3>
      <div class="identification-info">
        <div class="pure-form">
          <h4>Pure MBDB (HCl salt)</h4>
          <ul>
            <li><strong>Appearance:</strong> White to off-white crystalline powder</li>
            <li><strong>Texture:</strong> Fine crystalline powder, similar to MDMA</li>
            <li><strong>Odor:</strong> Mild chemical smell, less distinctive than MDMA</li>
            <li><strong>Taste:</strong> Bitter, somewhat numbing but milder than MDMA</li>
            <li><strong>Solubility:</strong> Soluble in water, alcohol</li>
          </ul>
        </div>
        
        <div class="street-forms">
          <h4>Research Chemical Forms</h4>
          <ul>
            <li><strong>Powder:</strong> Most common form, usually in small quantities</li>
            <li><strong>Pressed pills:</strong> Rare, when available often mixed with other substances</li>
            <li><strong>Capsules:</strong> Sometimes pre-weighed by vendors</li>
            <li><strong>Crystal chunks:</strong> Larger crystalline pieces, less common</li>
          </ul>
        </div>
        
        <div class="adulterants-warning">
          <h4>笞・・Identification Challenges</h4>
          <p><strong>Research chemical status:</strong> Limited testing options, few reagent color changes documented</p>
          <p><strong>MDMA confusion:</strong> Similar appearance, only distinguishable by advanced testing</p>
          <p><strong>Vendor reliability:</strong> Quality varies significantly between sources</p>
          <p><strong>Purity concerns:</strong> Synthesis byproducts and starting materials may be present</p>
        </div>
      </div>
    </div>
    
    <div class="profile-section dosage">
      <h3>汳 Dosage Guidelines</h3>
      <div class="dosage-chart">
        <div class="dose-range threshold">
          <span class="range-label">Threshold</span>
          <span class="dose-amount">120-140mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range light">
          <span class="range-label">Light</span>
          <span class="dose-amount">140-170mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range common">
          <span class="range-label">Common</span>
          <span class="dose-amount">170-210mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range strong">
          <span class="range-label">Strong</span>
          <span class="dose-amount">210-250mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range heavy">
          <span class="range-label">Heavy</span>
          <span class="dose-amount">250mg+</span>
          <div class="dose-bar"></div>
        </div>
      </div>
      
      <div class="dosage-details">
        <h4>Dosage Considerations</h4>
        <ul>
          <li><strong>Higher doses needed:</strong> ~1.5-2x MDMA doses for similar effects</li>
          <li><strong>Longer duration:</strong> 6-8 hours vs MDMA's 4-6 hours</li>
          <li><strong>Gentler onset:</strong> More gradual come-up over 1-2 hours</li>
          <li><strong>Redosing:</strong> Not recommended due to extended duration</li>
          <li><strong>First time:</strong> Start with 170mg maximum</li>
          <li><strong>Body weight:</strong> ~2-3mg/kg for empathogenic effects</li>
        </ul>
      </div>
      
      <p class="dosage-note"><strong>Research Chemical Warning:</strong> Limited human studies exist. Start conservatively and allow extra time between uses.</p>
    </div>

    <div class="profile-section effects">
      <h3>笨ｨ Effects Profile</h3>
      
      <div class="effects-timeline">
        <h4>Timeline</h4>
        <div class="timeline-item">
          <span class="time">T+0:45-1:30</span>
          <span class="effect">Onset - gentle euphoria, calm energy</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+1:30-4:00</span>
          <span class="effect">Peak - deep empathy, emotional openness</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+4:00-7:00</span>
          <span class="effect">Plateau - sustained empathogenic effects</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+7:00-12:00</span>
          <span class="effect">Comedown - gradual, gentle return</span>
        </div>
      </div>

      <div class="effects-categories">
        <div class="effect-category positive">
          <h4>笨・Positive Effects</h4>
          <ul>
            <li>Deep emotional empathy and connection</li>
            <li>Enhanced introspection and self-reflection</li>
            <li>Gentle euphoria without intense rushing</li>
            <li>Increased emotional openness</li>
            <li>Peaceful, meditative headspace</li>
            <li>Less physical stimulation than MDMA</li>
            <li>Smoother, gentler comedown</li>
            <li>Enhanced appreciation for music and art</li>
          </ul>
        </div>
        
        <div class="effect-category negative">
          <h4>笶・Negative Effects</h4>
          <ul>
            <li>Mild jaw tension (less than MDMA)</li>
            <li>Possible nausea during onset</li>
            <li>Dilated pupils</li>
            <li>Mild hyperthermia</li>
            <li>Potential for mild next-day fatigue</li>
            <li>Possible emotional sensitivity post-experience</li>
          </ul>
        </div>
      </div>

      <div class="mbdb-characteristics">
        <h4>沍ｸ Unique MBDB Characteristics</h4>
        <div class="characteristic-comparison">
          <div class="comparison-item">
            <h5>vs. MDMA</h5>
            <ul>
              <li><strong>More gentle:</strong> Less intense physical stimulation</li>
              <li><strong>Longer lasting:</strong> Extended empathogenic plateau</li>
              <li><strong>More introspective:</strong> Enhanced self-reflection vs social effects</li>
              <li><strong>Smoother comedown:</strong> Less crash, gentler landing</li>
              <li><strong>Higher dose needed:</strong> ~1.5-2x MDMA dose</li>
            </ul>
          </div>
          <div class="comparison-item">
            <h5>Shulgin's Notes</h5>
            <p><em>"MBDB is to MDMA as a quiet conversation is to a loud party. The empathy is there, but it's gentler, more inward-looking, with less of the 'I love everyone' feeling and more of the 'I understand myself' feeling."</em></p>
          </div>
        </div>
      </div>
    </div>

    <div class="profile-section pharmacology">
      <h3>洫 Pharmacology & Neuroscience</h3>
      <div class="pharma-details">
        <h4>Primary Mechanism of Action</h4>
        <p>MBDB acts as a selective serotonin releasing agent with significantly less activity at dopamine and norepinephrine transporters compared to MDMA. The additional methyl group and structural changes result in a more selective serotonergic profile, explaining its gentler, less stimulating effects.</p>
        
        <h4>Detailed Receptor Pharmacology</h4>
        <div class="receptor-table">
          <div class="receptor-row">
            <span class="receptor-name"><strong>SERT (5-HT transporter)</strong></span>
            <span class="affinity">High affinity (primary target)</span>
            <span class="function">Empathogenic effects, emotional openness</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>NET (NE transporter)</strong></span>
            <span class="affinity">Much lower affinity than MDMA</span>
            <span class="function">Reduced stimulant effects vs MDMA</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>DAT (DA transporter)</strong></span>
            <span class="affinity">Very low affinity</span>
            <span class="function">Minimal euphoric rushing, gentler experience</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>5-HT2A receptor</strong></span>
            <span class="affinity">Weak activity</span>
            <span class="function">Minimal perceptual changes</span>
          </div>
        </div>

        <h4>Metabolism & Pharmacokinetics</h4>
        <div class="metabolism-details">
          <p><strong>Duration:</strong> 6-8 hours (longer than MDMA due to structural changes)</p>
          <p><strong>Metabolism:</strong> Limited data, likely similar hepatic pathways as MDMA</p>
          <p><strong>Peak effects:</strong> 1.5-3 hours after oral administration</p>
          <p><strong>Elimination:</strong> Likely renal excretion of metabolites</p>
          <p><strong>Research gap:</strong> Detailed pharmacokinetic studies not available</p>
        </div>

        <h4>Structural Differences from MDMA</h4>
        <div class="structural-analysis">
          <p><strong>Key modification:</strong> Additional methyl group on the alpha carbon</p>
          <p><strong>Result:</strong> Altered binding profile favoring serotonin over dopamine/norepinephrine</p>
          <p><strong>Pharmacological consequence:</strong> More selective empathogenic effects with less stimulation</p>
          <p><strong>Duration impact:</strong> Structural changes may affect metabolism rate</p>
        </div>

        <h4>Limited Research Profile</h4>
        <ul>
          <li><strong>Shulgin synthesis:</strong> Documented in PiHKAL with limited human trials</li>
          <li><strong>No clinical studies:</strong> Research limited to underground reports</li>
          <li><strong>Safety profile:</strong> Extrapolated from MDMA research, not independently verified</li>
          <li><strong>Neurotoxicity:</strong> Unknown, potentially lower than MDMA due to reduced dopaminergic activity</li>
          <li><strong>Tolerance development:</strong> Likely similar to other empathogens</li>
        </ul>
      </div>
    </div>

    <div class="profile-section safety">
      <h3>笞・・Safety & Harm Reduction</h3>
      
      <div class="safety-grid">
        <div class="safety-item critical">
          <h4>泅ｨ Research Chemical Warnings</h4>
          <ul>
            <li><strong>Limited safety data:</strong> No formal toxicology studies</li>
            <li><strong>Unknown long-term effects:</strong> Neurotoxicity profile unclear</li>
            <li><strong>Quality control issues:</strong> Synthesis purity varies</li>
            <li><strong>Legal ambiguity:</strong> Status can change rapidly</li>
          </ul>
        </div>
        
        <div class="safety-item precautions">
          <h4>泝｡・・Harm Reduction Practices</h4>
          <ul>
            <li>Start with lower doses due to limited human data</li>
            <li>Use reagent testing when possible</li>
            <li>Longer breaks between uses (3+ months recommended)</li>
            <li>Stay hydrated but avoid over-hydration</li>
            <li>Cool environment to prevent hyperthermia</li>
            <li>Trusted, calm setting for first experience</li>
          </ul>
        </div>
      </div>

      <div class="research-chemical-considerations">
        <h4>洫ｪ Research Chemical Considerations</h4>
        <div class="consideration-grid">
          <div class="consideration-item">
            <h5>Source Reliability</h5>
            <p>Vendor quality varies significantly. Synthesis byproducts and impurities common. Third-party testing when possible.</p>
          </div>
          <div class="consideration-item">
            <h5>Dosage Uncertainty</h5>
            <p>Limited human dosage data. Individual sensitivity varies. Conservative approach essential.</p>
          </div>
          <div class="consideration-item">
            <h5>Legal Status</h5>
            <p>Unscheduled in most countries but analogue laws may apply. Status can change without warning.</p>
          </div>
        </div>
      </div>

      <div class="contraindications">
        <h4>泅ｫ Contraindications</h4>
        <p><strong>Do not use if you have:</strong> Heart conditions, psychiatric medications, liver problems, or any condition that contraindicates MDMA use. Extra caution needed due to limited safety research.</p>
      </div>
    </div>

    <div class="profile-section interactions">
      <h3>笞暦ｸ・Drug Interactions</h3>
      
      <div class="interaction-levels">
        <div class="interaction dangerous">
          <h4>沐ｴ Dangerous (Extrapolated from MDMA)</h4>
          <ul>
            <li><strong>MAOIs:</strong> Risk of serotonin syndrome</li>
            <li><strong>SSRIs/SNRIs:</strong> Serotonin syndrome risk, blunted effects</li>
            <li><strong>Tramadol:</strong> Increased seizure risk</li>
            <li><strong>DXM:</strong> Serotonin syndrome potential</li>
          </ul>
        </div>
        
        <div class="interaction risky">
          <h4>沺｡ Risky</h4>
          <ul>
            <li><strong>Stimulants:</strong> Cardiovascular strain, though likely less than MDMA</li>
            <li><strong>Alcohol:</strong> Unknown interaction, potential for increased toxicity</li>
            <li><strong>Other empathogens:</strong> Cross-tolerance, increased neurotoxicity risk</li>
          </ul>
        </div>
        
        <div class="interaction unknown">
          <h4>笶・Unknown</h4>
          <ul>
            <li><strong>Most substances:</strong> Limited interaction data available</li>
            <li><strong>Psychedelics:</strong> Interaction profile not established</li>
            <li><strong>Research chemicals:</strong> Unpredictable combinations</li>
          </ul>
        </div>
      </div>

      <div class="interaction-note">
        <p><strong>Research Chemical Disclaimer:</strong> Most interaction data is extrapolated from MDMA research. Unknown interactions possible due to structural differences.</p>
      </div>
    </div>

    <div class="profile-section legal">
      <h3>笞厄ｸ・Legal Status</h3>
      <div class="legal-info">
        <div class="legal-jurisdictions">
          <div class="jurisdiction">
            <h4>氈E氈E United States</h4>
            <p><strong>Unscheduled</strong> - Not explicitly controlled, but may fall under Federal Analogue Act as MDMA analogue.</p>
          </div>
          <div class="jurisdiction">
            <h4>氈E氈E United Kingdom</h4>
            <p><strong>Class A (likely)</strong> - Covered under generic empathogen legislation. Psychoactive Substances Act applies.</p>
          </div>
          <div class="jurisdiction">
            <h4>氈E氈E European Union</h4>
            <p><strong>Varies by country</strong> - Some countries have analogue laws covering MDMA-related compounds.</p>
          </div>
          <div class="jurisdiction">
            <h4>氈E氈E Australia</h4>
            <p><strong>Likely Schedule 9</strong> - May be covered under MDMA analogue provisions.</p>
          </div>
        </div>
        
        <div class="legal-considerations">
          <h4>笞・・Legal Considerations</h4>
          <ul>
            <li><strong>Analogue laws:</strong> May be treated as MDMA in jurisdictions with analogue legislation</li>
            <li><strong>Research chemical status:</strong> "Not for human consumption" labeling common</li>
            <li><strong>Rapid changes:</strong> Legal status can change quickly as governments update legislation</li>
            <li><strong>International shipping:</strong> Customs seizure risk varies by country</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section history">
      <h3>沒 History & Culture</h3>
      
      <div class="history-timeline">
        <div class="history-event">
          <span class="year">1986</span>
          <p>First synthesized by Alexander Shulgin as part of empathogen research</p>
        </div>
        <div class="history-event">
          <span class="year">1991</span>
          <p>Published in PiHKAL (Entry #109) with human trial reports</p>
        </div>
        <div class="history-event">
          <span class="year">1990s</span>
          <p>Limited underground circulation, overshadowed by MDMA popularity</p>
        </div>
        <div class="history-event">
          <span class="year">2000s</span>
          <p>Occasional availability through research chemical vendors</p>
        </div>
        <div class="history-event">
          <span class="year">2010s</span>
          <p>Renewed interest as MDMA alternatives sought by researchers</p>
        </div>
      </div>

      <div class="shulgin-legacy">
        <h4>洫ｪ Shulgin's Research</h4>
        <p>Alexander Shulgin developed MBDB as part of his systematic exploration of empathogenic compounds. His notes describe it as a "gentler, more introspective MDMA" with potential therapeutic applications. The substance never gained the cultural significance of MDMA but represents important research into selective empathogenic pharmacology.</p>
      </div>

      <div class="cultural-context">
        <h4>Cultural Impact</h4>
        <p>MBDB remains largely within research and psychonaut communities, never achieving mainstream recognition. Its gentler profile makes it of interest to those seeking MDMA's empathogenic benefits with less physical intensity, though limited availability restricts widespread use.</p>
      </div>
    </div>

    <div class="profile-section research">
      <h3>沐ｬ Current Research</h3>
      
      <div class="research-status">
        <div class="research-item">
          <h4>Limited Academic Interest</h4>
          <p>No formal clinical trials or academic research programs currently investigating MBDB. Interest limited to theoretical pharmacological studies.</p>
        </div>
        
        <div class="research-item">
          <h4>Underground Reports</h4>
          <p>User experiences suggest potential therapeutic applications similar to MDMA but with gentler effects profile. However, these remain anecdotal without scientific validation.</p>
        </div>
        
        <div class="research-item">
          <h4>Neurotoxicity Questions</h4>
          <p>Unknown whether MBDB shares MDMA's neurotoxic potential. Its reduced dopaminergic activity might suggest lower toxicity, but research is needed.</p>
        </div>
        
        <div class="research-item">
          <h4>Therapeutic Potential</h4>
          <p>Theoretical interest in gentler empathogen for therapy applications, but no formal research programs exist.</p>
        </div>
      </div>

      <div class="research-gaps">
        <h4>Critical Research Gaps</h4>
        <ul>
          <li><strong>Safety profile:</strong> No formal toxicology or safety studies</li>
          <li><strong>Pharmacokinetics:</strong> Detailed absorption, metabolism, elimination data missing</li>
          <li><strong>Therapeutic efficacy:</strong> No controlled studies of therapeutic potential</li>
          <li><strong>Long-term effects:</strong> Unknown consequences of repeated use</li>
          <li><strong>Drug interactions:</strong> Limited interaction data beyond theoretical extrapolation</li>
        </ul>
      </div>
    </div>

  </div>

  <div class="substance-resources">
    <h3>沒 Additional Resources</h3>
    <div class="resources-grid">
      <div class="resource-item">
        <h4>Research Sources</h4>
        <ul>
          <li><a href="https://www.erowid.org/library/books_online/pihkal/pihkal109.shtml">PiHKAL Entry #109</a> - Shulgin's original notes</li>
          <li><a href="https://psychonautwiki.org/">PsychonautWiki</a> - User experiences and basic information</li>
          <li><a href="https://bluelight.org/">Bluelight Forums</a> - Community experiences</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Harm Reduction</h4>
        <ul>
          <li><a href="https://dancesafe.org/">DanceSafe</a> - General empathogen harm reduction</li>
          <li><a href="https://rollsafe.org/">RollSafe</a> - MDMA harm reduction (applicable principles)</li>
          <li><a href="https://tripsit.me/">TripSit</a> - Real-time harm reduction support</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Testing & Analysis</h4>
        <ul>
          <li><a href="https://drugsdata.org/">DrugsData.org</a> - Professional analysis service</li>
          <li><a href="https://bunkpolice.com/">Bunk Police</a> - Reagent testing supplies</li>
          <li><strong>Note:</strong> Limited reagent data available for MBDB specifically</li>
        </ul>
      </div>
    </div>
  </div>

  <div class="research-chemical-disclaimer">
    <h3>笞・・Research Chemical Disclaimer</h3>
    <p>MBDB is a research chemical with limited human safety data. All information is based on limited reports, theoretical pharmacology, and extrapolation from related compounds. Users assume significant unknown risks. This information is for educational purposes only and does not constitute medical or legal advice.</p>
  </div>

</div>

